Psychedelics 2.0: After MDMA’s Setback, Where Does the Field Go – and What About Psilocybin? Medically reviewed by PChina Jin LI (李锦) Institute of toxicology , Academy of Military Medical Sciences, Beijing Introduction The last decade has witnessed a rapid resurgence of interest in psychedelic-assisted therapies for psychiatric disorders. Driven by limited progress with conventional…

Long COVID and Psychiatry: Phenotypes, Mechanisms, and Care Pathways Medically reviewed by PChina Jin LI (李锦) Institute of toxicology, Academy of Military Medical Sciences, Beijing Introduction Since the early waves of the pandemic, it has become clear that for a substantial minority of individuals, recovery from acute SARS-CoV-2 infection does not mark the end of…

Adolescents, Social Media, and Mental Health (2025 Update) Introduction Few topics in adolescent psychiatry have generated as much public concern or as much conflicting evidence as the impact of social media on youth mental health. Headlines warn of an epidemic of loneliness, depression, and anxiety among teens tethered to their phones, while others emphasize the…

Antipsychotics Beyond Dopamine: The Muscarinic Turn Medically reviewed by Paul E. Bebbington, MA, MPhil, FRCPsych; Phern-Chern Tor, MBBS; and Pichet Udomratn, MD | Last updated: 12 June 2025 Introduction For more than half a century, antipsychotic treatment has rested on the pharmacological foundation of dopamine D2 antagonism: the idea that attenuating hyperdopaminergic signaling in striatal circuits would quell hallucinations,…